Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pfizer
The CP-945,598 program was terminated on November 3, 2008 due to changing regulatory perspectives on the risk/benefit profile of the CB1 class and likely new regulatory requirements for approval. No safety issues were involved in the termination decision.
Age
18–70
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Subjects must be overweight (BMI 27- 50 kg/m2)
Subjects must have type 2 diabetes mellitus
You may not be if
Pregnancy
Serious or unstable current or past medical conditions
Clareo Health | A 1-Year Study On The Effects Of CP-945,598 For The Treatment Of Obesity In Overweight Type 2 Diabetic Patients
